Intravenous Infusions (XGHA:IIL) YoY EBITDA Growth: 0.00% (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XGHA:IIL Intravenous Infusions Ltd XGHA:IIL
3 GF Score
Price GHS0.75
View Full Analysis

What is Intravenous Infusions YoY EBITDA Growth?

Intravenous Infusions XGHA:IIL -1.32% 3 YoY EBITDA Growth is 0.00% as of . 20. GuruFocus rates XGHA:IIL with a GF Score™ of 3/100.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Intravenous Infusions's YoY EBITDA Growth for the quarter that ended in . 20 was 0.00%.

Intravenous Infusions's EBITDA per Share for the six months ended in . 20 was GHS0.00.

Intravenous Infusions YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Intravenous Infusions's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intravenous Infusions YoY EBITDA Growth Chart

Intravenous Infusions Annual Data
Trend
YoY EBITDA Growth

Intravenous Infusions Semi-Annual Data
YoY EBITDA Growth
XGHA:IIL
3GF Score
Intravenous Infusions Ltd XGHA:IIL
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intravenous Infusions YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Intravenous Infusions's YoY EBITDA Growth for the fiscal year that ended in . 20 is calculated as:

YoY EBITDA Growth (A: . 20 )
=(EBITDA per Share (A: . 20 )-EBITDA per Share (A: . 20 ))/ | EBITDA per Share (A: . 20 ) |
=(-)/ | |
=N/A %

Intravenous Infusions's YoY EBITDA Growth for the quarter that ended in . 20 is calculated as:

YoY EBITDA Growth (Q: . 20 )
=(EBITDA per Share (Q: . 20 )-EBITDA per Share (Q: . 20 )) / | EBITDA per Share (Q: . 20 ) |
=(-)/ | |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 0.00% mean?
Intravenous Infusions (XGHA:IIL) has a YoY EBITDA Growth of 0.00% as of . 20. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Intravenous Infusions and its competitors.
Is Intravenous Infusions' YoY EBITDA Growth too high?
Intravenous Infusions' current YoY EBITDA Growth is 0.00%. Overall, Intravenous Infusions has a GF Score™ of 3/100, reflecting its overall financial health beyond just this single metric.
How does Intravenous Infusions' YoY EBITDA Growth compare to PTLF and PCYN?
Intravenous Infusions' YoY EBITDA Growth of 0.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Intravenous Infusions and its competitors. Intravenous Infusions's current YoY EBITDA Growth is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current YoY EBITDA Growth of 0.00%. The current YoY EBITDA Growth is 0.00%. Intravenous Infusions' overall GF Score™ is 3/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current YoY EBITDA Growth is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intravenous Infusions Business Description

Address Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.
3GF Score

Get the complete analysis for XGHA:IIL

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

GHS0.75
Price